Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313 in healthy volunteers
NCT02532049Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Oct 2015
- Primary completion
- May 2017
- Modality
- Prophylactic Vaccines, Nanoparticles, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAd63 Pfs25-IMX313 and Pfs25-IMX313 in malaria, sponsored by University of Oxford. Started Oct 2015; status: completed.
02
Drugs
ChAd63 Pfs25-IMX313Pfs25-IMX313
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02532049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532049.